The efficacy of activating other pro-tumorigenic pathways, such as PKA signaling by CW008, Oct4 signaling by OAC2, and PI3K signaling by YS49, can be evaluated in inhibiting varying types of breast cancer. The gene discussed is POU5F1; the disease is breast cancer.